Pharmaceutical regulatory support for the Saudi Arabian market
The Saudi Food and Drug Authority (SFDA) regulates pharmaceutical products in the Kingdom of Saudi Arabia, including their registration, importation, manufacturing, distribution and ongoing regulatory compliance.
Structured regulatory support for the Saudi market
Entering the Saudi pharmaceutical market requires an understanding of SFDA requirements, applicable registration pathways, technical dossier expectations, manufacturing standards and post-approval obligations.
RIAR Consulting provides regulatory consulting and documentation support to pharmaceutical manufacturers, marketing authorisation applicants and international companies seeking to register and maintain their pharmaceutical products in Saudi Arabia.
We also support manufacturers and distributors of medical devices, IVDs, cosmetics and other regulated products, aligning technical documentation, regulatory strategy and submission execution with current SFDA regulations and guidance documents.
Our SFDA pharmaceutical regulatory services
RIAR Consulting supports pharmaceutical companies in navigating the Saudi regulatory framework through structured regulatory planning, technical documentation and market-specific compliance support.
- 01
Regulatory strategy and product registration
- Assessment of SFDA regulatory requirements for pharmaceutical products
- Product classification and registration pathway assessment
- Regulatory gap assessment and submission planning
- Support for new pharmaceutical product registration
- Requirements for generic and other pharmaceutical products
- Support for imported and locally manufactured products
- 02
CTD/eCTD dossier preparation and review
- Preparation and review of Common Technical Document (CTD) dossiers
- eCTD documentation and submission-readiness support, as applicable
- Administrative and technical dossier compilation
- Review of quality, safety and efficacy documentation
- Module 1 Saudi-specific documentation review
- Technical consistency and completeness checks before submission
- 03
CMC and pharmaceutical quality documentation
- Drug substance and drug product documentation
- Manufacturing process descriptions and controls
- Pharmaceutical development and quality documentation
- Specifications and analytical method documentation
- Stability study documentation
- 04
GMP and manufacturing site compliance
- GMP documentation review and gap assessment
- Manufacturing site documentation support
- Review of relevant quality management documentation
- Preparation for applicable SFDA GMP requirements and inspections
- Addressing identified documentation gaps
- 05
Import and manufacturing regulatory support
- Assessment of applicable pharmaceutical import requirements
- Support with manufacturing and import documentation
- Review of manufacturing site and product information
- Coordination of documentation and licensing requirements
- 06
Variations, renewals and post-approval support
- Support for marketing authorisation variations
- Assessment of changes to composition, manufacturing processes, specifications and packaging
- Renewal documentation support
- Regulatory impact assessment for post-approval changes
- Maintenance and updating of regulatory documentation
- 07
Regulatory queries and deficiency management
- Review of SFDA queries and requests for additional information
- Preparation and coordination of technical responses
- Support in resolving dossier deficiencies
- Review of supporting documents and regulatory correspondence
- Submission follow-up and regulatory communication
- 08
Regulatory lifecycle management
- Ongoing regulatory requirements assessment
- Monitoring of relevant SFDA regulatory updates
- Regulatory impact assessment of new requirements
- Support for applicable post-authorisation commitments
- Documentation management throughout the product lifecycle
How we support SFDA device and cosmetic compliance
For medical devices, IVDs and cosmetics, we assist clients across the SFDA regulatory lifecycle, including:
- Product classification and regulatory pathway assessment
- SFDA Product Classification System (PCS) submissions
- Medical Device Marketing Authorization (MDMA) applications
- Authorized Representative (AR) agreement support
- Importation and Distribution License (MDIL) applications
- UDI registration in SAUDI-D
- Cosmetics registration via eCOSMA
- Renewals, updates, and variations
- Regulatory query handling and authority communication
Each project is handled through a structured workflow aligned with SFDA’s Medical Device Regulations (MDS), guidance documents, and technical requirements.
Why choose RIAR Consulting for SFDA
Our approach minimizes delays, avoids rejection risks, and improves regulatory predictability.
- 01
Strong understanding of SFDA device bundling and classification rules
- 02
Practical experience handling complex, multi-device portfolios
- 03
Focus on reducing unnecessary applications and rework
- 04
Clear documentation mapping aligned with SFDA folder structures
- 05
High approval success rate through compliant strategy
- 06
Dedicated SFDA regulatory consultants managing each submission
Dedicated expertise ensuring compliant SFDA approvals
Each SFDA project is led by a dedicated regulatory consultant with hands-on experience in SFDA medical device and cosmetic registrations.
The lead consultant oversees:
- Regulatory strategy and application structuring
- Document review and gap assessment
- Submission execution and follow-ups
- Client communication and progress reporting
This ensures accountability, clarity, and consistent quality throughout the project lifecycle.
How VERA 2.0 supports this sector
Products registered with the SFDA must come from sites that meet applicable GMP requirements and may be inspected. VERA 2.0 adds continuous visibility into the manufacturing conditions behind a registration.
- VERA 2.0
GMP manufacturing visibility
Continuous visibility into facility, environmental and equipment conditions relevant to GMP, where supported by connected systems.
- VERA 2.0
Earlier identification of abnormal conditions
Anomaly identification flags unusual operating patterns so authorised personnel can investigate before they affect a batch.
- VERA 2.0
Inspection-readiness records
Structured records of events, observations and advisories support internal reviews ahead of SFDA GMP inspections.
- VERA 2.0
Change and variation context
Operational context on equipment and process conditions supports assessment of manufacturing changes that may require a variation.
VERA 2.0 is an advisory decision-support system. It does not write to or control plant systems, and it does not replace the site’s quality management system, validated records or regulatory determinations. Capabilities depend on the systems connected at each site.
Looking to register your pharmaceutical product in Saudi Arabia?
Whether you are entering the Saudi market for the first time, registering a new pharmaceutical product or maintaining an existing marketing authorisation, RIAR Consulting can support your regulatory requirements. Connect with our team to discuss your SFDA registration and compliance needs.